Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Context The improved remission and complication rates of current transsphenoidal surgery
warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in …

Pituitary adenomas are tumors that arise in the anterior pituitary gland. They are the third
most common cause of central nervous system (CNS) tumors among adults. Most adenomas …

Purpose Renewed interest in transsphenoidal surgery (TSS) as a therapeutic option for
prolactinomas has emerged. Methods Based on contemporary literature and own …

Objective Clinical paradigms and consensus recommend dopamine agonists (DAs) as the
primary treatment for prolactinomas. However, medically treated patients also encounter …

Purpose To review our institutional experience with the surgical management of
prolactinomas through the endoscopic endonasal approach with specific focus on …

Background: This meta-analysis aims to evaluate the long-term efficacy of medication
treatment vs. surgery treatment in patients with prolactinomas. Methods: An electronic …

Objective Prolactin-secreting tumors respond well to medical management, with a few
patients requiring surgery. We conducted a systematic review and meta-analysis to study the …

Abstract Purpose In Prolactinomas, surgery or radiation are reserved for DA failure due to
tumor resistance, intolerance to medication-induced side-effects, or patient preference. This …

Dopamine agonists (DAs) are well recognized as the first-line therapy for prolactinomas due
to their efficacy in achieving tumoral shrinkage and normoprolactinemia. However, it …